Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in vitro

Pharmaceutical Research

Volumn 14, Issue 12, 1997, Pages 1744-1749

  Lange, Katharina ^a   Gysler, Anja ^a   Bader, Michael ^b   Kleuser, Burkhard ^a   Korting, Hans Christian ^c   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Benefit risk ratio; Fibroblasts; Interleukins; Keratinocytes; Topical glucocorticoids

Indexed keywords

BETAMETHASONE; BETAMETHASONE VALERATE; DESOXIMETASONE; GLUCOCORTICOID; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PREDNICARBATE; PREDNISOLONE 17 ETHYL CARBONATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIODEGRADATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; SKIN FIBROBLAST; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE 17-VALERATE; CELL DIVISION; CELLS, CULTURED; DESOXIMETASONE; FIBROBLASTS; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; KERATINOCYTES; PREDNISOLONE; RNA, MESSENGER; SKIN; THYMIDINE;

EID: 0031422404     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012183914011     Document Type: Article

References (24)

1. M. Schäfer-Korting, H. C. Korting, M. J. Kerscher, and S. Lenhard. Clin. Pharmacol. Ther. 54:448-456 (1993).
2. M. Schäfer-Korting, M.-H. Schmid, and H. C. Korting. Drug Safety 14:375-385 (1996).
3. P. J. Dykes, S. Hill, and R. Marks. Assessment of the atrophogenic potential of corticosteroids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions. In E. Christophers, E. Schöpf, A. M. Kligman, and R. B. Stoughton (eds.), Topical corticosteroid therapy. A novel approach to safer drugs, Raven Press, New York, 1988, pp. 111-19.
4. H.-C. Korting, D. Vieluf, and M. Kerscher. Eur. J. Clin. Pharmacol. 42:159-161 (1992).
5. R. Niedner and E. Schöpf. Clinical efficacy of topical glucocorticoid preparations and other types of dermatics in inflammatory skin diseases, particularly in atopic dermatitis. In H. C. Korting and H. I. Maibach (eds.), Topical glucocorticoids with increased benefit/risk-ratio, Karger, Basel, 1993, pp. 157-169.
6. A. Aliaga, M. Rodriguez, M. Armijo, J. Bravo, A. López Avila, J. M. Mascara, J. Ferrando, R. Del Rio, R. Lozano, and A. Balaguer. Int. J. Dermatol. 35:131-132 (1996).
7. C. L. Kutsch, D. A. Norris, and W. P. Arend. J. Invest. Dermatol. 101:79-85 (1993).
8. M. Goldring and S. R. Goldring. Critical reviews in eukaryotic gene expression 1:301-329 (1991).
9. N. Auphan, J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. Science 270:286-290 (1995).
10. R. I. Scheinman, P. C. Cogswell, A. K. Lofquist, and A. S. Baldwin. Science 270:283-286 (1995).
11. A. Ray and K. Prefontaine. Proc. Natl. Acad. Sci. USA 91:752-756 (1994).
12. R. W. Groves, T. Rauschmayr, K. Nakamura, S. Sarkar, I. R. Williams, and T. S. Kupper. J. Clin. Invest. 98:336-44 (1996).
13. T. S. Kupper and R. W. Groves: J. Invest. Dermatol. 105:62S-66S (1995).
14. I. L. A. Boxman, C. Ruwhof, O C. Boerman, C. W. G. M. Löwik, and M. Ponec: Arch. Dermatol. Res. 288:391-398 (1996).
15. M. Pagé, N. Bejaoui, B. Cinq-Mars, and P. Lemieux. J. Immun. Pharmacol. 10:785-793 (1988).
16. T. Nishida, N. Nishino, M. Takano, K. Kawai, K. Bando, Y. Masui, S. Nakai, and Y. Hirai. Biochem. Biophys. Res. Commun. 143:345-352 (1987).
17. H. Wong, W. D. Anderson, T. Cheng, and K. T. Riabowol. Anal. Biochem. 223:251-258 (1994).
18. J. Y. Tso, X. H. Sun, T. H. Kao, K. S. Reece, and R. Wu. Nucl. Acids Res. 13:2485-2502 (1985).
19. A. Gysler, K. Lange, H. C. Korting, M. Schäfer-Korting. Pharm. Res. 14:793-797 (1997).
20. M. Ponec. Glucocorticoid receptors. In H. C. Korting and H. I. Maibach (eds), Topical glucocorticoids with increased benefit/ risk ratio, Karger, Basel, 1993, pp. 20-28.
21. M. Ponec. Arch. Dermatol. Res. 275:334-344 (1983).
22. G. Würthwein, S. Rehder, and P. Rhodewald. Pharmazeutische Zeitung Wissenschaft, 4:161-166 (1992).
23. Ch. M. Bamberger, A.-M. Bamberger, M. DeCastro, and G. P. Chrousos. J. Clin. Invest. 95:2435-2441 (1995).
24. M. Schäfer-Korting. Topical glucocorticoids: What has been achieved? What is still to be done? In H. C. Korting and H. I. Maibach (eds.), Topical glucocorticoids with increased benefit/ risk ratio, Karger, Basel, 1993, pp. 192-201.